Revvity Inc. (RVTY) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Revvity Inc. (RVTY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

120.39

-2.31 (-1.88%)

At close: Jan 14, 2025, 3:59 PM

120.50

0.09%

Pre-market Jan 15, 2025, 05:14 AM EST

undefined% (undefined)

Bid	113.23
Market Cap	14.65B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.09
PE Ratio (ttm)	57.61
Forward PE	n/a
Analyst	Buy

Ask	127.85
Volume	531,964
Avg. Volume (20D)	895,800
Open	122.63
Previous Close	122.70
Day's Range	119.25 - 122.97
52-Week Range	97.32 - 129.50
Beta	undefined

About RVTY

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences resea...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Jul 6, 1965

Employees 11,000

Stock Exchange NYSE

Ticker Symbol RVTY

Website https://www.perkinelmer.com

Analyst Forecast

According to 13 analyst ratings, the average rating for RVTY stock is "Buy." The 12-month stock price forecast is $135, which is an increase of 12.13% from the latest price.

Buy 61.54%

Hold 38.46%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Revvity Inc. is scheduled to release its earnings on Jan 31, 2025, before market opens.
Analysts project revenue of $730.10M, reflecting a 4.91% YoY growth and earnings per share of 1.38, making a 10.40% increase YoY.

Why Price Moved

2 days ago · Source

+7.74%

Revvity shares are trading higher after the compan... Unlock content with Pro Subscription

5 months ago · Source

+9.07%

Revvity shares are trading higher after the company reported strong Q2 earnings and raised its guidance.

News

2 days ago · zacks.com

RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test

Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.

2 days ago · businesswire.com

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 20...

2 weeks ago · zacks.com

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's strong product portfolio raises optimism about the stock.

4 weeks ago · businesswire.com

Revvity to Present at J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. Presiden...

1 month ago · seekingalpha.com

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics

Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%) ...

1 month ago · zacks.com

Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?

1 month ago · businesswire.com

Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critic...

2 months ago · benzinga.com

These Analysts Revise Their Forecasts On Revvity Following Q3 Results

Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday.

2 months ago · zacks.com

RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised

Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.

2 months ago · seekingalpha.com

Revitty (RVTY) Q3 2024 Earnings Call Transcript

Revitty Incorporated (NYSE:RVTY ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Prahlad Singh - President, Chief Executive Officer Max Krakowiak - Senior Vice Presi...

2 months ago · zacks.com

Here's What Key Metrics Tell Us About Revvity (RVTY) Q3 Earnings

Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Str...

2 months ago · zacks.com

Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates

Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago.

2 months ago · reuters.com

Revvity cuts 2024 revenue forecast amid biotech spending slowdown

Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development.

2 months ago · businesswire.com

Revvity Announces Financial Results for the Third Quarter of 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024. The Company reported GAAP earnings per share of $0.77, as ...

2 months ago · zacks.com

Revvity to Report Q3 Earnings: What's in Store for the Stock?

RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.

2 months ago · zacks.com

Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · businesswire.com

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on Febru...

2 months ago · zacks.com

Revvity Shares Decline Despite Launch of Transcribe AI Solution

RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.

2 months ago · businesswire.com

Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company's sustainability, social and governance strategy, initiatives and perfo...